+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

HIV Injection Market Size, Share & Trends Analysis Report By Distribution Channel (Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others), By Regional Outlook and Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 143 Pages
  • March 2024
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5949670
The Global HIV Injection Market size is expected to reach $2.8 billion by 2030, rising at a market growth of 17.6% CAGR during the forecast period.

North America, particularly the United States, has a relatively high prevalence of HIV compared to other regions. Therefore, the North America segment captured $368.07 million revenue in the market in 2022. This high prevalence creates a substantial demand for HIV medications, including injectable therapies. North America is at the forefront of HIV research and treatment, leading to the development of new and innovative HIV medications, including injectable therapies.



The escalating prevalence of HIV/AIDS necessitates the development of more efficacious treatment modalities to alleviate symptoms and sustain life. This increased demand has driven pharmaceutical companies and researchers to develop new and innovative HIV injections to meet the growing needs of patients. Thus, the increasing prevalence of HIV is supporting the growth of the market.

Additionally, the innovative formulations offer several advantages over traditional oral medications, driving their adoption and increasing demand in the market. Injectable therapies typically require less frequent dosing than oral medications, which can be particularly beneficial for patients with difficulty adhering to complex medication schedules. Therefore, the development of innovative injectable formulations for the treatment of HIV/AIDS has had a positive impact on the demand for HIV injections.

However, the high cost of HIV treatment, including injectable medications, remains a significant barrier to access for many people living with HIV/AIDS, particularly in low- and middle-income countries. The cost of HIV treatment can include not only the price of the medication itself but also the cost of regular monitoring, laboratory tests, and healthcare provider visits, which can quickly add up to a substantial financial burden for patients. Hence, the high cost might hamper the expansion of the market.

The COVID-19 pandemic had a significant impact on the market, affecting various aspects of the supply chain and patient access to treatment. Raw material shortages and manufacturing delays followed disruptions in the global supply chain, which affected HIV medications, including injectable therapies. These disruptions impacted their availability in some regions, potentially leading to treatment interruptions for patients. Thus, the pandemic affected the market negatively

By Distribution Channel Analysis

Based on distribution channel, the market is divided into hospital pharmacy, drug stores & retail pharmacies, and others. The hospital pharmacy segment procured 46.2% revenue share in the market in 2022. Hospitals, clinics, and other healthcare facilities are major distribution points for HIV injections. They receive medications from pharmaceutical companies or wholesalers and distribute them to patients as part of their treatment regimens.



By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The LAMEA segment witnessed 5.3% revenue share in the market in 2022. The LAMEA region has a relatively high prevalence of HIV, with certain countries in sub-Saharan Africa experiencing particularly high rates of infection. Governments in the LAMEA region have implemented various initiatives to address the HIV/AIDS epidemic, including funding for HIV/AIDS programs and improving access to treatment.

List of Key Companies Profiled

  • GlaxoSmithKline PLC (GSK)
  • Gilead Sciences, Inc.
  • ImmunityBio, Inc.
  • F.Hoffmann-La Roche Ltd.
  • Theratechnologies Inc.
  • Viriom, Inc.
  • AbbVie, Inc.
  • Brii Biosciences Limited
  • Shionogi & Co., Ltd.
  • Boehringer Ingelheim International GmbH

Market Report Segmentation

By Distribution Channel
  • Hospital Pharmacy
  • Drugs Stores & Retail Pharmacies
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global HIV Injection Market, by Distribution Channel
1.4.2 Global HIV Injection Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Opportunities
3.2.3 Market Restraints
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis
Chapter 4. Global HIV Injection Market by Distribution Channel
4.1 Global Hospital Pharmacy Market by Region
4.2 Global Drugs Stores & Retail Pharmacies Market by Region
4.3 Global Others Market by Region
Chapter 5. Global HIV Injection Market by Region
5.1 North America HIV Injection Market
5.1.1 North America HIV Injection Market by Distribution Channel
5.1.1.1 North America Hospital Pharmacy Market by Country
5.1.1.2 North America Drugs Stores & Retail Pharmacies Market by Country
5.1.1.3 North America Others Market by Country
5.1.2 North America HIV Injection Market by Country
5.1.2.1 US HIV Injection Market
5.1.2.1.1 US HIV Injection Market by Distribution Channel
5.1.2.2 Canada HIV Injection Market
5.1.2.2.1 Canada HIV Injection Market by Distribution Channel
5.1.2.3 Mexico HIV Injection Market
5.1.2.3.1 Mexico HIV Injection Market by Distribution Channel
5.1.2.4 Rest of North America HIV Injection Market
5.1.2.4.1 Rest of North America HIV Injection Market by Distribution Channel
5.2 Europe HIV Injection Market
5.2.1 Europe HIV Injection Market by Distribution Channel
5.2.1.1 Europe Hospital Pharmacy Market by Country
5.2.1.2 Europe Drugs Stores & Retail Pharmacies Market by Country
5.2.1.3 Europe Others Market by Country
5.2.2 Europe HIV Injection Market by Country
5.2.2.1 Germany HIV Injection Market
5.2.2.1.1 Germany HIV Injection Market by Distribution Channel
5.2.2.2 UK HIV Injection Market
5.2.2.2.1 UK HIV Injection Market by Distribution Channel
5.2.2.3 France HIV Injection Market
5.2.2.3.1 France HIV Injection Market by Distribution Channel
5.2.2.4 Russia HIV Injection Market
5.2.2.4.1 Russia HIV Injection Market by Distribution Channel
5.2.2.5 Spain HIV Injection Market
5.2.2.5.1 Spain HIV Injection Market by Distribution Channel
5.2.2.6 Italy HIV Injection Market
5.2.2.6.1 Italy HIV Injection Market by Distribution Channel
5.2.2.7 Rest of Europe HIV Injection Market
5.2.2.7.1 Rest of Europe HIV Injection Market by Distribution Channel
5.3 Asia Pacific HIV Injection Market
5.3.1 Asia Pacific HIV Injection Market by Distribution Channel
5.3.1.1 Asia Pacific Hospital Pharmacy Market by Country
5.3.1.2 Asia Pacific Drugs Stores & Retail Pharmacies Market by Country
5.3.1.3 Asia Pacific Others Market by Country
5.3.2 Asia Pacific HIV Injection Market by Country
5.3.2.1 China HIV Injection Market
5.3.2.1.1 China HIV Injection Market by Distribution Channel
5.3.2.2 Japan HIV Injection Market
5.3.2.2.1 Japan HIV Injection Market by Distribution Channel
5.3.2.3 India HIV Injection Market
5.3.2.3.1 India HIV Injection Market by Distribution Channel
5.3.2.4 South Korea HIV Injection Market
5.3.2.4.1 South Korea HIV Injection Market by Distribution Channel
5.3.2.5 Singapore HIV Injection Market
5.3.2.5.1 Singapore HIV Injection Market by Distribution Channel
5.3.2.6 Malaysia HIV Injection Market
5.3.2.6.1 Malaysia HIV Injection Market by Distribution Channel
5.3.2.7 Rest of Asia Pacific HIV Injection Market
5.3.2.7.1 Rest of Asia Pacific HIV Injection Market by Distribution Channel
5.4 LAMEA HIV Injection Market
5.4.1 LAMEA HIV Injection Market by Distribution Channel
5.4.1.1 LAMEA Hospital Pharmacy Market by Country
5.4.1.2 LAMEA Drugs Stores & Retail Pharmacies Market by Country
5.4.1.3 LAMEA Others Market by Country
5.4.2 LAMEA HIV Injection Market by Country
5.4.2.1 Brazil HIV Injection Market
5.4.2.1.1 Brazil HIV Injection Market by Distribution Channel
5.4.2.2 Argentina HIV Injection Market
5.4.2.2.1 Argentina HIV Injection Market by Distribution Channel
5.4.2.3 UAE HIV Injection Market
5.4.2.3.1 UAE HIV Injection Market by Distribution Channel
5.4.2.4 Saudi Arabia HIV Injection Market
5.4.2.4.1 Saudi Arabia HIV Injection Market by Distribution Channel
5.4.2.5 South Africa HIV Injection Market
5.4.2.5.1 South Africa HIV Injection Market by Distribution Channel
5.4.2.6 Nigeria HIV Injection Market
5.4.2.6.1 Nigeria HIV Injection Market by Distribution Channel
5.4.2.7 Rest of LAMEA HIV Injection Market
5.4.2.7.1 Rest of LAMEA HIV Injection Market by Distribution Channel
Chapter 6. Company Profiles
6.1 GlaxoSmithKline PLC (GSK)
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.1.5 SWOT Analysis
6.1 Gilead Sciences, Inc.
6.1.1 Company overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expenses
6.1.4 SWOT Analysis
6.2 ImmunityBio, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expenses
6.2.5 SWOT Analysis
6.3 F. Hoffmann-La Roche Ltd.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 SWOT Analysis
6.4 Theratechnologies Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Research & Development Expenses
6.4.4 SWOT Analysis
6.5 Viriom, Inc.
6.5.1 Company Overview
6.5.2 SWOT Analysis
6.6 AbbVie, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.6.5 SWOT Analysis
6.7 Brii Biosciences Limited
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.7.4 SWOT Analysis
6.8 Shionogi & Co., Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expenses
6.8.4 SWOT Analysis
6.9 Boehringer Ingelheim International GmbH
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional & Segmental Analysis
6.9.4 Research & Development Expenses
6.9.5 SWOT Analysis
Chapter 7. Winning Imperatives of HIV Injection Market

Companies Mentioned

  • GlaxoSmithKline PLC (GSK)
  • Gilead Sciences, Inc.
  • ImmunityBio, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Theratechnologies Inc.
  • Viriom, Inc.
  • AbbVie, Inc.
  • Brii Biosciences Limited
  • Shionogi & Co., Ltd.
  • Boehringer Ingelheim International GmbH

Methodology

Loading
LOADING...